Zyclara (imiquimod) / Mochida, Viatris, Bausch Health - LARVOL DELTA

Establishment of a novel lupus mesenteric vasculitis mouse model and exploration of its exacerbation mechanisms. (PubMed, Front Immunol) - "In our preliminary experiments, we found that NZBWF1 (BWF1) mice, a spontaneous SLE mouse model, developed bloody stools when treated with imiquimod, a Toll-like receptor (TLR) 7 agonist...Additionally, our findings suggest that bacteria influence the induction and exacerbation of LMV pathogenesis, and that intestinal propionate may be involved in maintaining homeostasis. In the future, this LMV mouse model may contribute to the development of new diagnostic and therapeutic methods."

Journal • Preclinical • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus • Vasculitis

TRPV4 Regulates Imiquimod (IMQ)-Induced Psoriasis via CaMKKβ/AMPK and Calmodulin/Akt-Mediated Autophagic Signaling Pathways in Juvenile Murine Keratinocytes. (PubMed, Dermatopathology (Basel)) - " Both CaMKKβ/AMPK and Calmodulin/Akt signaling pathways, as downstream components of TRPV4, are involved in IMQ-induced psoriasis: lower IMQ dosage activates AMPK, thereby preventing psoriasis by ROS clearance, whereas higher IMQ dosage activates Calmodulin and exacerbates psoriasis. Our findings reveal the potential values of targeting TRP-related channels in IMQ-induced psoriasis."

Journal • Preclinical • Dermatology • Immunology • Inflammation • Psoriasis • AMPK • TRPV4

Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. (PubMed, J Control Release) - "The platform co-delivers a hydrogen sulfide (H₂S)-responsive prodrug of toll-like Toll-like receptor 7/8 (TLR7/8) agonist imiquimod (IMQ) using a reactive oxygen species (ROS)-sensitive, targeted nanocarrier...This RT-primed, sequentially activated therapy profoundly enhances antitumor immunity by inducing immunogenic cell death (ICD), activating antigen-presenting cells (APCs), and overcoming systemic immunosuppression, culminating in durable tumor regression and immunological memory. This study highlights a chemistry-driven approach to spatially and temporally confine immune activation to the tumor site, effectively broadening the therapeutic window and transforming RT-induced biochemical changes into a precise trigger for systemic immunity."

Journal • Oncology

Mechanism of electroacupuncture inhibiting psoriasis recurrence by regulating CD8+ memory T cells based on the TRAF2/NF-κB signaling pathway (PubMed, Zhen Ci Yan Jiu) - "EA can effectively alleviate symptoms of recurrent psoriasis. Its underlying mechanism may be related to inhibiting the activation of the TRAF2/NF-κB signaling pathway and specifically down-regulating the level of CD8+ memory T cells."

Journal • Dermatology • Immunology • Oncology • Psoriasis • CD4 • CD8 • CXCL10 • CXCL9 • CXCR3 • IL15 • IL17A • IL6 • ITGAE • RELA • TNFA

Distinct migration behaviors of monocyte-derived versus resident langerhans cells drive the pathogenesis of imiquimod-induced skin inflammation. (PubMed, J Dermatol Sci) - "rLCs and moLCs display distinct migratory behaviors and exert divergent immunological functions during IMQ-induced skin inflammation. Lesion-retained moLCs are associated with local inflammatory responses, whereas lymph node-migratory rLCs are linked to immunoregulatory activity."

IO biomarker • Journal • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • CCR7 • CD4 • IL17A • IL22 • PD-L1

Vulvar intraepithelial neoplasia and vulvar cancer (PubMed, Dermatologie (Heidelb)) - "The treatment of dVIN is surgical, while treatment of uVIN can be ablative, surgical or medicinal (imiquimod being preferred)...Primary prevention of HPV-induced lesions is highly effective through primary HPV vaccination. Secondary prevention of dVIN/HPV-independent invasive carcinoma appears to be achievable through consistent maintenance therapy of the underlying lichen sclerosus with highly potent topical corticosteroids."

Journal • Review • Dermatology • Gynecologic Cancers • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor • Vulvar Cancer

Non-surgical therapies for localized non-melanoma skin cancer in older adults: A review. (PubMed, J Geriatr Oncol) - "Specifically, topical agents such as 5-fluorouracil, imiquimod, tirbanibulin, retinoids, and trichloroacetic acid offer effective, less-invasive options for superficial lesions but rely heavily on adherence, which may be compromised in cognitively impaired or functionally-limited individuals. Intralesional therapies (including 5-fluorouracil and methotrexate), on the other hand, provide high clearance rates with minimal systemic toxicity, while also reducing patient responsibility and daily application...Furthermore, this review emphasizes that across all modalities, NST selection must prioritize geriatric principles, balancing efficacy with safety, comfort, functional status, cognitive capacity, support systems, and patient preferences. As the aging population grows and NMSC numbers expand in parallel, individualized, patient-centered care and expanded older adult-focused research are essential to optimizing treatment outcomes for older adults."

Journal • Review • Alzheimer's Disease • Basal Cell Carcinoma • Cognitive Disorders • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

What's new in the treatment of scars (EADV 2026) - "*Other Treatments: Treatments for acne scars include topical retinoids, oral isotretinoin with fractional ablative CO2 laser, botulinum toxin A for surgical scars, and emerging therapies like dupilumab for keloids. Various treatments, including imiquimod cream, radiation therapy, laser treatment, and others, have been shown to reduce keloid recurrence rates and improve scar appearance. Genetic differences between keloids and other scar types suggest targeted therapeutic approaches could be beneficial.Objectives:1. To appreciate differences between keloids and other scars.2."

Acne Vulgaris • Aesthetic Medicine • Fibrosis

Update on anal dysplasia and anal cancer (PubMed, Dermatologie (Heidelb)) - "Therapeutically, destructive methods (such as electrocautery or trichloroacetic acid) and local immunomodulatory therapies (imiquimod) are used. Combining different therapeutic modalities is frequently a feasible strategy. For advanced anal cancer, recent studies such as POD1UM-303/InterAACT‑2 (immunotherapy with retifanlimab), as well as procedures like plasma HPV-ctDNA measurement (liquid biopsy) and dose-escalated/sparing radiation therapy, show promising results and give a perspective for the ongoing revision of the S3 guideline on anal cancer."

Journal • Review • Anal Carcinoma • Gynecologic Cancers • Human Immunodeficiency Virus • Infectious Disease • Oncology • Solid Tumor • Vulvar Cancer

Personalized neoantigen vaccine with or without pembrolizumab in patients with microsatellite-stable metastatic colorectal cancer (AACR 2025) - "Vaccines were given subcutaneously with topical imiquimod adjuvant on weeks 0, 1, 3-6, 9, 12, 15, 18, 21, 27, 30, 39, and 51. Personalized immunotherapy with NeoAg-VAX +/- anti-PD-1 was feasible, safe, and immunogenic in MSS mCRC pts. Although clinical responses were modest, spatial proteomics revealed key features of tumor immune contexture that may inform future therapeutic approaches."

Clinical • IO biomarker • Metastases • Tumor-specific neoantigens • Colorectal Cancer • Oncology • Solid Tumor • IFNG

Inhibiting HuR-Mediated mRNA Stabilization Attenuates Psoriasis-Like Inflammation in Preclinical Models. (PubMed, Psoriasis (Auckl)) - "In vivo, TM11 reduced psoriasis-like symptoms in Imiquimod-treated mice, reducing Psoriasis Area and Severity Index (PASI) scores, systemic inflammation and histological alterations...Overall, these findings highlight HuR as a key driver of psoriasis pathogenesis and provide preclinical evidence that pharmacological modulation of HuR activity, by TM11 treatment, could provide a conceptual therapeutic rationale for psoriasis, potentially contributing to the reduction of keratinocyte hyperproliferation and immune activation while favouring the restoration of skin homeostasis. However, further preclinical and clinical validation will be required to establish its translational feasibility."

Journal • Preclinical • Dermatology • Immunology • Inflammation • Psoriasis • BIRC5 • CD69 • FABP5 • IFNG • IL2RA

Intradermal hepatitis B vaccination with or without Imiquimod in cirrhosis after prior vaccine nonresponse: A Randomised Trial. (PubMed, JHEP Rep) - P2 | "Intradermal HBV revaccination significantly improves seroconversion in non-responder patients with ACLD compared with IM vaccination, without additional benefit from imiquimod. These results support further evaluation of intradermal vaccination without imiquimod in a phase 3 trial."

Journal • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation

Ginsenoside Rk3 modulates glutamine metabolism and inhibits Th17 cell differentiation via gut microbiota regulation to ameliorate psoriasis. (PubMed, J Nat Med) - "Network pharmacology was first employed to predict potential targets for the action of Rk3 on psoriasis and an imiquimod (IMQ)-induced psoriasis mice model was used to investigate the palliative effect of Rk3 on psoriasis...Rk3-mediated regulation of glutamine metabolism exerts an inhibition effect on the conversion of glutamine to glutamate, suppresses Th17 cell differentiation and alleviates psoriasis via the IL-6/JAK1-STAT3 signaling axis. Overall, our research elucidates Rk3's mechanism of action in ameliorating psoriasis and highlights its potential as a gut microbiota modulator for psoriasis treatment."

Journal • Dermatology • Immunology • Psoriasis • IL6 • JAK1

Papaverine ameliorates psoriasis-like skin inflammation by regulating immune cell differentiation and RAGE-S100A7 axis in an imiquimod-induced murine model. (PubMed, J Immunol) - "These findings suggest that papaverine ameliorates psoriasis-like symptoms through inhibition of proinflammatory cytokines and suppression of aberrant plasma cell differentiation. In conclusion, papaverine demonstrates therapeutic potential as a candidate for the treatment of psoriasis."

Journal • Preclinical • Dermatitis • Dermatology • Immunology • Inflammation • Oncology • Psoriasis • BCL6 • CD4 • CD8 • IFNG • IL1B • IL22 • IL6 • KRT10 • PRDM1 • SDC1 • XBP1

Imiquimod-Induced Lupus-Like Reaction: A Diagnostic Challenge and Pathophysiological Insight (EADV 2026) - No abstract available

Immunology • Inflammatory Arthritis • Lupus

Anatomical Biomechanics and the Efficacy of Postoperative Imiquimod in Keloid Recurrence: A Systematic Review and Meta-Analysis (EADV 2026) - No abstract available

Retrospective data • Review • Fibrosis

Cutaneous psoriasis triggered by topical imiquimod in a patient with latent genetic predisposition (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Psoriasis

Characteristics, Management, and Outcomes of Uncommon Imiquimod-Induced Cutaneous Eruptions: A Systematic Review (EADV 2026) - No abstract available

Review

Refractory anal intraepithelial neoplasia grade III successfully treated with Imiquimod (EADV 2026) - No abstract available

Topical Imiquimod in Mycosis Fungoides: A Systematic Review of Published Clinical Evidence (EADV 2026) - No abstract available

Clinical • Review • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Imiquimod-Induced Vitiligo-Like Hypopigmentation: A Comprehensive Review of Clinical Presentations, Mechanisms, and Therapeutic Implications (EADV 2026) - No abstract available

Clinical • Review • Dermatology • Immunology • Vitiligo

Effects of calcipotriene/betamethasone dipropionate foam combined with phototherapy in an imiquimod-induced mouse model of psoriasis (EADV 2026) - No abstract available

Preclinical • Dermatology • Immunology • Psoriasis

The Effect of Oral Administration of Borage (Borago officinalis) and Flaxseed (Linum usitatissimum) Seed Oils on Treatment in an Imiquimod-Induced Murine Psoriasis Model (EADV 2026) - No abstract available

Preclinical • Dermatology • Immunology • Psoriasis

Topical Imiquimod for Lentigo Maligna in a Nonagenarian (EADV 2026) - No abstract available

Melanoma

Cutaneous B-cell lymphoproliferative process following topical imiquimod treatment (EADV 2026) - No abstract available

Oncology